Alembic Pharmaceuticals Ltd
APLLTDAlembic Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +15.7% in a year against a −14.3% price move.
The sharpest disagreement: annual EPS moved +15.7% against a −14.3% price move — the market has not yet caught up with the delivery.
The price is building a base (6 weeks in) while the P/E sits at the 44th percentile of its own 11-year range. Underneath, the last four quarters read improving — profit +11.7% year on year, and 90% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Alembic Pharmaceuticals Ltd trades at ₹811, building a base and 6 weeks into that stage. That is +0.0% against its own 200-day average. It sits at 55% of a 52-week range of ₹674 to ₹925. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 14 straight weeks.
Today the stock is building a base — week 6 of stage 1. At ₹811 it trades +0.0% versus its 200-day average and sits at 55% of its 52-week range (₹674–₹925).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +32% while the NIFTY 500 moved +267% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 14 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Alembic Pharmaceuticals Ltd trades at 21.4× P/E, mid-range by its own standards (44th percentile). Its long-run median P/E is 23.6×, measured across 10.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 21.4× is mid-range by its own standards (44th percentile), against a long-run median of 23.6× measured over 10.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +15.7% against a −14.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +1.2%/yr price move, ~−6.4%/yr came from earnings growth and ~+7.6 pp from the multiple (expanding); over 10y, of the +2.5%/yr price move, ~−0.5%/yr came from earnings growth and ~+3.0 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.
Solved at its 13 June 2026 price, Alembic Pharmaceuticals Ltd was paying for profit growth of about 13.7% a year. Profit itself has compounded −0.7% a year over the past 10 years. Today the market pays 21.4× P/E, the 44th percentile of its own 11-year range.
What the two numbers say together. The multiple is unremarkable against its own past, and the growth the price is paying for is above what this company has actually delivered.
How to hold this number: it is a reading of one day's price, taken on 13 June 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.
Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Alembic Pharmaceuticals Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −4.4% at the trough to +14.6% off a 4-quarter-old trough, ROCE holding at 13.7%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +10.1% | +9.1% | +6.4% | +8.8% |
| Profit | +15.3% | +25.2% | −10.2% | −0.7% |
| EPS | +15.7% | +25.4% | −10.1% | −1.1% |
| Share price | −14.3% | +2.0% | +1.2% | +2.5% |
4-Factor Sector Score
43.7/100 — rank 28 of 44 in Pharma - Formulators · 94% evidence confidence
Alembic Pharmaceuticals Ltd scores 43.7 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 28. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 16.4 + 8.4 + 12.5 + 6.4 = 43.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Alembic Pharmaceuticals Ltd reported ₹2,150 Cr of revenue in the Jun 26 quarter, +25.7% year on year. That is the 12th straight quarter of year-on-year growth. Over 10 years it has compounded at 8.8% a year. The last full year, FY26, came in at ₹7,345 Cr. The last four reported quarters add to ₹7,784 Cr.
FY26 revenue came in at ₹7,345 Cr (+10.1% on the year), capping 10 years at 8.8% compound. The latest quarter (Jun 26) printed ₹2,150 Cr, +25.7% year on year — the 12th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +14.2% growth against the decade's 8.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +14.1% over the last 4 quarters against +11.1%/yr over the last 8 — stabilising; TTM profit +14.6% vs +4.7%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Alembic Pharmaceuticals Ltd's operating margin is 15.0% in the Jun 26 quarter, −1.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0% to 32.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 15.0%, −1.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 12.0%–32.0%.
🚨 Why the margin moved: operating margin went −1.0 pp year on year while gross margin went −5.0 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Alembic Pharmaceuticals Ltd earned ₹172 Cr of net profit in the Jun 26 quarter, +11.7% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹671 Cr. The 10-year compound rate is −0.7%. That is 8.0% of the quarter's revenue. The same quarter a year earlier earned ₹154 Cr.
Jun 26 profit was ₹172 Cr, +11.7% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹671 Cr (+15.3%), and the 10-year compound rate is −0.7%.
Why profit moved: revenue contributed +25.7% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +14.1% vs revenue +14.2%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 90% of Alembic Pharmaceuticals Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹783 Cr of operating cash against ₹671 Cr of profit. After ₹722 Cr of capital spending, ₹61.0 Cr was left as free cash.
FY26: operating cash of ₹783 Cr against reported profit of ₹671 Cr, leaving free cash of ₹61.0 Cr after ₹722 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 90% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 90%: the cash cycle stretched 120 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Alembic Pharmaceuticals Ltd's cash conversion cycle runs 381 days in FY26, up from 261 days in FY21. Capital spending ran ₹1,636 Cr over the last 3 years. At FY26 sales of ₹7,345 Cr each day of that cycle holds about ₹20.1 Cr, so roughly ₹7,667 Cr sits inside the business at any moment.
FY26: debtors at 73 days, inventory at 462 days — roughly 15.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 381 days, looser than FY21's 261.
The full loop: cash goes out to suppliers and production on day 0; stock waits 462 days to sell; customers pay about 73 days after that; and suppliers themselves are paid at 154 days — netting out to the 381-day cycle.
In money terms: at FY26 sales of ₹7,345 Cr, each day of the cycle holds about ₹20.1 Cr — so the 381-day loop keeps roughly ₹7,667 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,636 Cr over the last 3 fiscal years against ₹871 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹683 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Alembic Pharmaceuticals Ltd earns a ROCE of 13% in FY26. That is up from a trough of 7% in FY23. Return on invested capital clears the cost of that capital by −0.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 9.1% net margin on 0.84× asset turns.
FY26 ROCE is 13%, recovered from a FY23 trough of 7% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 9.1% net margin × 0.84× asset turns × 1.54× balance-sheet leverage ≈ 11.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 11.3% − 12.0% = a −0.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Alembic Pharmaceuticals Ltd carries total debt of ₹1,430 Cr against shareholder equity of ₹5,669 Cr as of Mar 26, a debt-to-equity of 0.25 — effectively unlevered. On the annual view that ratio went from 0.14 in FY22 to 0.25 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹1,430 Cr against shareholder equity of ₹5,669 Cr — a debt-to-equity of 0.25. On the annual view, debt-to-equity went from 0.14 (FY22) to 0.25 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Alembic Pharmaceuticals Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.3 points over the same window, to 69.9%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: +0.5 points over 8 quarters to 15.9%; Promoters: +0.3 points over 8 quarters to 69.9%; Foreign institutions: −0.2 points over 8 quarters to 4.2%.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Alembic Pharmaceuticals Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Kwality Pharmaceuticals Ltd539997 | 73.7/100Favorable setup82% evidence | LEADER | 31.1/35 Revenue 37.9% · PAT 88.4% · OPM change 3 pp 95% evidence | 17.8/25 ROCE 24.1% · OPM 25% 76% evidence | 6.2/20 P/E 46.3× · PEG — 50% evidence | 18.6/20 RS sector 72.7% · RS bench 113.3% · 1Y 288.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.1 + 17.8 + 6.2 + 18.6 = 73.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Glenmark Pharmaceuticals LtdGLENMARK | 71.1/100Favorable setup100% evidence | TURNING | 30.8/35 Revenue 32.9% · PAT 100% · OPM change 2 pp 100% evidence | 18.2/25 ROCE 39.8% · OPM 20% 100% evidence | 12.4/20 P/E 21.9× · PEG 1.43 100% evidence | 9.7/20 RS sector -11.1% · RS bench 15.2% · 1Y 17.9%3 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 18.2 + 12.4 + 9.7 = 71.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Bliss GVS Pharma LtdBLISSGVS | 69.5/100Favorable setup82% evidence | LEADER | 29.0/35 Revenue 20.6% · PAT 25.7% · OPM change 7 pp 95% evidence | 14.8/25 ROCE 16.9% · OPM 27% 76% evidence | 6.0/20 P/E 55.7× · PEG — 50% evidence | 19.7/20 RS sector 102.4% · RS bench 147.9% · 1Y 362.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 14.8 + 6 + 19.7 = 69.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Ipca Laboratories LtdIPCALAB | 67.9/100Favorable setup82% evidence | BREAKING OUT | 26.3/35 Revenue 10.6% · PAT 68% · OPM change 6 pp 95% evidence | 15.8/25 ROCE 17% · OPM 24% 76% evidence | 11.0/20 P/E 36.4× · PEG — 50% evidence | 14.8/20 RS sector -0.6% · RS bench 28.3% · 1Y 47.5%10 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 15.8 + 11 + 14.8 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Lupin LtdLUPIN | 66.8/100Favorable setup93% evidence | ASLEEP | 29.6/35 Revenue 28.2% · PAT 49.2% · OPM change 2 pp 100% evidence | 19.3/25 ROCE 29.9% · OPM 30% 100% evidence | 16.3/20 P/E 16.1× · PEG 0.54 65% evidence | 1.6/20 RS sector -26.2% · RS bench -4% · 1Y 7.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29.6 + 19.3 + 16.3 + 1.6 = 66.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -26.2% and the one-year return is 7.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 6Emcure Pharmaceuticals LtdEMCURE | 66.3/100Favorable setup75% evidence | LEADER | 27.3/35 Revenue 18.4% · PAT 32.2% · OPM change 1 pp 95% evidence | 18.2/25 ROCE 24% · OPM 21% 76% evidence | 9.9/20 P/E 36.4× · PEG — 15% evidence | 10.9/20 RS sector -2.5% · RS bench 25.5% · 1Y 44.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 27.3 + 18.2 + 9.9 + 10.9 = 66.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Corona Remedies LtdCORONA | 65.2/100Favorable setup73% evidence | BREAKING OUT | 23.0/35 Revenue 18% · PAT 19.3% · OPM change 2 pp 100% evidence | 20.4/25 ROCE 33.3% · OPM 22% 100% evidence | 11.8/20 P/E 64.4× · PEG 1.18 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 23 + 20.4 + 11.8 + 10 = 65.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Fredun Pharmaceuticals LtdFREDUN | 64.9/100Mixed-positive evidence74% evidence | 26.7/35 Revenue 91.5% · PAT 100% · OPM change 0 pp 95% evidence | 13.0/25 ROCE 21.3% · OPM 14% 95% evidence | 9.3/20 P/E 53.3× · PEG — 15% evidence | 15.9/20 RS sector 24.1% · RS bench 96.2% · 1Y 9.2%4 of 12 weeks ahead 70% evidence | |
| Exact sum: 26.7 + 13 + 9.3 + 15.9 = 64.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Accent Microcell LtdACCENTMIC | 64.5/100Mixed-positive evidence63% evidence | LEADER | 17.5/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 18.9/25 ROCE 24.9% · OPM 16% 95% evidence | 8.7/20 P/E 39.7× · PEG — 50% evidence | 19.4/20 RS sector 44.8% · RS bench 83.4% · 1Y 160.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 17.5 + 18.9 + 8.7 + 19.4 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Caplin Point Laboratories LtdCAPLIPOINT | 61.8/100Mixed-positive evidence100% evidence | LEADER | 19.0/35 Revenue 15% · PAT 19.6% · OPM change 0 pp 100% evidence | 17.7/25 ROCE 24.2% · OPM 35% 100% evidence | 9.4/20 P/E 31.5× · PEG 1.52 100% evidence | 15.7/20 RS sector 5.8% · RS bench 36.1% · 1Y 28.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 17.7 + 9.4 + 15.7 = 61.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Rubicon Research LtdRUBICON | 57.6/100Mixed-positive evidence73% evidence | BREAKING OUT | 24.1/35 Revenue 46.8% · PAT 91.4% · OPM change 2 pp 100% evidence | 17.9/25 ROCE 28.4% · OPM 24% 100% evidence | 5.6/20 P/E 105× · PEG 2.63 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 24.1 + 17.9 + 5.6 + 10 = 57.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 12Marksans Pharma LtdMARKSANS | 57.4/100Mixed-positive evidence87% evidence | BREAKING OUT | 25.8/35 Revenue 19.6% · PAT 48% · OPM change 9 pp 100% evidence | 15.8/25 ROCE 18.8% · OPM 25% 100% evidence | 6.3/20 P/E 28.9× · PEG 2.85 65% evidence | 9.5/20 RS sector -18.1% · RS bench 58.3% · 1Y 95%11 of 11 weeks ahead 70% evidence |
| Exact sum: 25.8 + 15.8 + 6.3 + 9.5 = 57.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Ajanta Pharma LtdAJANTPHARM | 56.3/100Mixed-positive evidence100% evidence | BREAKING OUT | 21.3/35 Revenue 20.2% · PAT 22.2% · OPM change -1 pp 100% evidence | 19.6/25 ROCE 34.5% · OPM 26% 100% evidence | 5.5/20 P/E 38.9× · PEG 2.31 100% evidence | 9.9/20 RS sector -5.3% · RS bench 22.1% · 1Y 35.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 21.3 + 19.6 + 5.5 + 9.9 = 56.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 14Strides Pharma Science LtdSTAR | 55.9/100Mixed-positive evidence75% evidence | TURNING | 20.6/35 Revenue 8.1% · PAT 79.1% · OPM change -1 pp 95% evidence | 13.3/25 ROCE 18.3% · OPM 18% 76% evidence | 11.2/20 P/E 18.8× · PEG — 15% evidence | 10.8/20 RS sector -4.1% · RS bench 24% · 1Y 32.9%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 13.3 + 11.2 + 10.8 = 55.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Wockhardt LtdWOCKPHARMA | 54.3/100Mixed-positive evidence74% evidence | TURNING | 24.9/35 Revenue 18.4% · PAT 100% · OPM change 11 pp 74% evidence | 5.3/25 ROCE 7.5% · OPM 21% 100% evidence | 8.8/20 P/E 88.8× · PEG — 15% evidence | 15.3/20 RS sector 10.9% · RS bench 42% · 1Y 47.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 5.3 + 8.8 + 15.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16RPG Life Sciences LtdRPGLIFE | 52.6/100Mixed-positive evidence93% evidence | LEADER | 11.9/35 Revenue 11.9% · PAT -34.1% · OPM change 1 pp 100% evidence | 17.5/25 ROCE 25.7% · OPM 22% 100% evidence | 11.1/20 P/E 38.2× · PEG 1.43 65% evidence | 12.1/20 RS sector -8.1% · RS bench 19.1% · 1Y 13.5%11 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 17.5 + 11.1 + 12.1 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17ERIS Lifesciences LtdERIS | 52.6/100Mixed-positive evidence76% evidence | BASING | 20.4/35 Revenue 9.6% · PAT 62.2% · OPM change -2 pp 95% evidence | 14.3/25 ROCE 14.1% · OPM 34% 76% evidence | 11.9/20 P/E 28.6× · PEG — 50% evidence | 6.0/20 RS sector -13.8% · RS bench -5% · 1Y -21.6%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.4 + 14.3 + 11.9 + 6 = 52.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Akums Drugs & Pharmaceuticals LtdAKUMS | 51.3/100Mixed-positive evidence75% evidence | LEADER | 13.2/35 Revenue 9.2% · PAT -15.8% · OPM change 2 pp 95% evidence | 10.9/25 ROCE 14.9% · OPM 15% 76% evidence | 9.6/20 P/E 40× · PEG — 15% evidence | 17.6/20 RS sector 15.9% · RS bench 48% · 1Y 68.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 10.9 + 9.6 + 17.6 = 51.3 · Decision use: Price leads the evidence: RS versus the benchmark is 48%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 19Suven Life Sciences LtdSUVEN | 51.0/100Mixed-positive evidence67% evidence | LEADER | 19.8/35 Revenue 25% · PAT -80% · OPM change -997 pp 74% evidence | 2.2/25 ROCE -79.5% · OPM — 84% evidence | 10.0/20 P/E — · PEG — 0% evidence | 19.0/20 RS sector 29.3% · RS bench 63% · 1Y 60%12 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 2.2 + 10 + 19 = 51 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Zydus Lifesciences LtdZYDUSLIFE | 49.3/100Mixed-negative evidence100% evidence | FADING | 11.9/35 Revenue 21.1% · PAT -2.5% · OPM change -8 pp 100% evidence | 16.7/25 ROCE 21.1% · OPM 24% 100% evidence | 13.7/20 P/E 22.9× · PEG 1.23 100% evidence | 7.0/20 RS sector -11.7% · RS bench 14.3% · 1Y 10.4%9 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 16.7 + 13.7 + 7 = 49.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 21J B Chemicals & Pharmaceuticals LtdJBCHEPHARM | 47.1/100Mixed-negative evidence96% evidence | 10.6/35 Revenue 5.9% · PAT 7.4% · OPM change -2 pp 88% evidence | 20.6/25 ROCE 25.4% · OPM 22% 100% evidence | 3.9/20 P/E 53.8× · PEG 2.34 100% evidence | 12.0/20 RS sector -0.3% · RS bench 23.5% · 1Y 40.2%3 of 4 weeks ahead to 2026-07-19 100% evidence | |
| Exact sum: 10.6 + 20.6 + 3.9 + 12 = 47.1 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 22Lincoln Pharmaceuticals LtdLINCOLN | 46.8/100Mixed-negative evidence87% evidence | ASLEEP | 15.1/35 Revenue 10% · PAT 11.5% · OPM change 0 pp 95% evidence | 15.3/25 ROCE 16.3% · OPM 15% 95% evidence | 10.8/20 P/E 13× · PEG — 50% evidence | 5.6/20 RS sector -15.1% · RS bench 9.9% · 1Y 11.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 15.3 + 10.8 + 5.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Alkem Laboratories LtdALKEM | 45.1/100Mixed-negative evidence82% evidence | ASLEEP | 14.6/35 Revenue 13.4% · PAT -5.5% · OPM change -2 pp 95% evidence | 17.4/25 ROCE 21.2% · OPM 20% 76% evidence | 11.6/20 P/E 26.8× · PEG — 50% evidence | 1.5/20 RS sector -28.5% · RS bench -6.5% · 1Y -4.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.6 + 17.4 + 11.6 + 1.5 = 45.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Aurobindo Pharma LtdAUROPHARMA | 44.8/100Mixed-negative evidence100% evidence | LEADER | 16.5/35 Revenue 9.1% · PAT 9.5% · OPM change 1 pp 100% evidence | 12.3/25 ROCE 12.9% · OPM 21% 100% evidence | 4.8/20 P/E 25.6× · PEG 2.67 100% evidence | 11.2/20 RS sector -1.3% · RS bench 26.9% · 1Y 60.9%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.5 + 12.3 + 4.8 + 11.2 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Sun Pharmaceutical Industries LtdSUNPHARMA | 44.2/100Mixed-negative evidence100% evidence | TURNING | 16.9/35 Revenue 11.4% · PAT 16.5% · OPM change -2 pp 100% evidence | 17.3/25 ROCE 20.5% · OPM 29% 100% evidence | 4.3/20 P/E 35× · PEG 3.8 100% evidence | 5.7/20 RS sector -19.4% · RS bench 4.7% · 1Y 15.5%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.9 + 17.3 + 4.3 + 5.7 = 44.2 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 26Kilitch Drugs (India) LtdKILITCH | 44.1/100Mixed-negative evidence87% evidence | FADING | 13.9/35 Revenue 14% · PAT 9.3% · OPM change -1 pp 95% evidence | 9.2/25 ROCE 13.4% · OPM 6.5% 95% evidence | 14.2/20 P/E 21.6× · PEG — 50% evidence | 6.8/20 RS sector -15.6% · RS bench 10% · 1Y 0.6%8 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 9.2 + 14.2 + 6.8 = 44.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 27Gufic BioSciences LtdGUFICBIO | 44.0/100Mixed-negative evidence94% evidence | BREAKING OUT | 23.1/35 Revenue 16.6% · PAT 17.7% · OPM change 3 pp 100% evidence | 9.8/25 ROCE 12.3% · OPM 18% 100% evidence | 2.3/20 P/E 58× · PEG 4.78 100% evidence | 8.8/20 RS sector -18.4% · RS bench 26.1% · 1Y 19.2%11 of 11 weeks ahead 70% evidence |
| Exact sum: 23.1 + 9.8 + 2.3 + 8.8 = 44 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Alembic Pharmaceuticals Ltdthis pageAPLLTD | 43.7/100Mixed-negative evidence94% evidence | BREAKING OUT | 16.4/35 Revenue 14.1% · PAT 14.6% · OPM change -1 pp 100% evidence | 8.4/25 ROCE 12.6% · OPM 15% 100% evidence | 12.5/20 P/E 21.4× · PEG 1.74 100% evidence | 6.4/20 RS sector -24.1% · RS bench 1.5% · 1Y -14.3%4 of 11 weeks ahead 70% evidence |
| Exact sum: 16.4 + 8.4 + 12.5 + 6.4 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Amrutanjan Health Care LtdAMRUTANJAN | 43.2/100Mixed-negative evidence87% evidence | BASING | 13.2/35 Revenue 10.7% · PAT -1.1% · OPM change -2.9 pp 95% evidence | 14.9/25 ROCE 24.8% · OPM 6.1% 95% evidence | 14.3/20 P/E 22.8× · PEG — 50% evidence | 0.8/20 RS sector -37.2% · RS bench -17% · 1Y -36.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 13.2 + 14.9 + 14.3 + 0.8 = 43.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 30Mankind Pharma LtdMANKIND | 42.9/100Mixed-negative evidence100% evidence | BASING | 16.8/35 Revenue 14.2% · PAT 8% · OPM change 2 pp 100% evidence | 13.8/25 ROCE 13.5% · OPM 26% 100% evidence | 8.2/20 P/E 44.2× · PEG 2.81 100% evidence | 4.1/20 RS sector -22.9% · RS bench 0.4% · 1Y -10.6%6 of 12 weeks ahead 100% evidence |
| Exact sum: 16.8 + 13.8 + 8.2 + 4.1 = 42.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31FDC LtdFDC | 41.9/100Mixed-negative evidence94% evidence | ASLEEP | 12.8/35 Revenue 3.5% · PAT 8.2% · OPM change -1 pp 100% evidence | 12.9/25 ROCE 15.4% · OPM 21% 100% evidence | 11.9/20 P/E 18× · PEG 2 100% evidence | 4.3/20 RS sector -25.1% · RS bench -11.7% · 1Y -27.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.8 + 12.9 + 11.9 + 4.3 = 41.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Indoco Remedies LtdINDOCO | 40.7/100Thin evidence · provisional58% evidence | TURNING | 20.2/35 Revenue 11.9% · PAT 100% · OPM change 5 pp 71% evidence | 4.4/25 ROCE 1% · OPM 9% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.1/20 RS sector -32.2% · RS bench 14.2% · 1Y -3.8%7 of 10 weeks ahead 70% evidence |
| Exact sum: 20.2 + 4.4 + 10 + 6.1 = 40.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Zim Laboratories LtdZIMLAB | 39.9/100Mixed-negative evidence79% evidence | LEADER | 9.6/35 Revenue 7.5% · PAT -60.6% · OPM change -3.3 pp 71% evidence | 6.1/25 ROCE 4.8% · OPM 2.6% 95% evidence | 5.8/20 P/E 202× · PEG — 50% evidence | 18.4/20 RS sector 25.7% · RS bench 59.5% · 1Y 87.3%11 of 12 weeks ahead 100% evidence |
| Exact sum: 9.6 + 6.1 + 5.8 + 18.4 = 39.9 · Decision use: Price leads the evidence: RS versus the benchmark is 59.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 34Torrent Pharmaceuticals LtdTORNTPHARM | 39.8/100Mixed-negative evidence100% evidence | BREAKING OUT | 16.6/35 Revenue 32.9% · PAT 7.7% · OPM change 2 pp 100% evidence | 14.2/25 ROCE 15.2% · OPM 34% 100% evidence | 0.8/20 P/E 84.6× · PEG 5.11 100% evidence | 8.2/20 RS sector -7.4% · RS bench 19.5% · 1Y 39%10 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 14.2 + 0.8 + 8.2 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Bafna Pharmaceuticals LtdBAFNAPH | 39.8/100Mixed-negative evidence60% evidence | TURNING | 11.5/35 Revenue -3.1% · PAT -5.8% · OPM change -11.3 pp 95% evidence | 7.3/25 ROCE 11.9% · OPM 3.4% 76% evidence | 8.7/20 P/E 91.5× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 84.4% · 1Y —3 of 3 weeks ahead 25% evidence |
| Exact sum: 11.5 + 7.3 + 8.7 + 12.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 36Bajaj Healthcare LtdBAJAJHCARE | 37.8/100Mixed-negative evidence87% evidence | BREAKING OUT | 9.8/35 Revenue 12.3% · PAT -59.1% · OPM change 1 pp 95% evidence | 10.3/25 ROCE 11.5% · OPM 17% 95% evidence | 11.9/20 P/E 20× · PEG — 50% evidence | 5.8/20 RS sector -29.8% · RS bench -7.1% · 1Y -22.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 10.3 + 11.9 + 5.8 = 37.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Natco Pharma LtdNATCOPHARM | 37.3/100Mixed-negative evidence100% evidence | ASLEEP | 3.0/35 Revenue -20.8% · PAT -32.5% · OPM change -18 pp 100% evidence | 14.1/25 ROCE 17.4% · OPM 25% 100% evidence | 19.1/20 P/E 12.8× · PEG 0.76 100% evidence | 1.1/20 RS sector -31.6% · RS bench -10.9% · 1Y -4.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 3 + 14.1 + 19.1 + 1.1 = 37.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 38Biocon LtdBIOCON | 36.2/100Mixed-negative evidence100% evidence | ASLEEP | 13.3/35 Revenue 9.8% · PAT -36.4% · OPM change 1 pp 100% evidence | 7.7/25 ROCE 3.6% · OPM 20% 100% evidence | 11.5/20 P/E 87.5× · PEG 0.82 100% evidence | 3.7/20 RS sector -22.1% · RS bench 1.3% · 1Y 7.4%6 of 12 weeks ahead 100% evidence |
| Exact sum: 13.3 + 7.7 + 11.5 + 3.7 = 36.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Bharat Parenterals LtdBPLPHARMA | 35.8/100Thin evidence · provisional58% evidence | 12.3/35 Revenue -11.2% · PAT 16% · OPM change -2.8 pp 71% evidence | 4.1/25 ROCE -1.9% · OPM 9.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.4/20 RS sector -12.8% · RS bench 24.2% · 1Y 10.6%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 12.3 + 4.1 + 10 + 9.4 = 35.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 40Cipla LtdCIPLA | 32.6/100Adverse evidence100% evidence | BASING | 4.6/35 Revenue 1.8% · PAT -37.7% · OPM change -9 pp 100% evidence | 12.3/25 ROCE 15.5% · OPM 17% 100% evidence | 12.0/20 P/E 30.8× · PEG 1.25 100% evidence | 3.7/20 RS sector -25.3% · RS bench -2.3% · 1Y -12.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 4.6 + 12.3 + 12 + 3.7 = 32.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Dr Reddys Laboratories LtdDRREDDY | 30.1/100Adverse evidence100% evidence | BASING | 3.7/35 Revenue -0.9% · PAT -44.6% · OPM change -14 pp 100% evidence | 11.7/25 ROCE 13% · OPM 11% 100% evidence | 13.3/20 P/E 30.2× · PEG 1.15 100% evidence | 1.4/20 RS sector -28% · RS bench -5.9% · 1Y -8.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 3.7 + 11.7 + 13.3 + 1.4 = 30.1 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 42Influx Healthtech LtdINFLUX | 59.8/100Thin evidence · provisional50% evidence | TURNING | 19.3/35 Revenue — · PAT — · OPM change -1 pp 26% evidence | 20.8/25 ROCE 40% · OPM 19% 95% evidence | 10.3/20 P/E 30.5× · PEG — 15% evidence | 9.4/20 RS sector -9.8% · RS bench 16% · 1Y 43.4%10 of 12 weeks ahead 70% evidence |
| Exact sum: 19.3 + 20.8 + 10.3 + 9.4 = 59.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43Syncom Healthcare LtdSYNCOM | 49.7/100Thin evidence · provisional31% evidence | 17.1/35 Revenue -69.4% · PAT 63.5% · OPM change — 16% evidence | 6.9/25 ROCE -20.2% · OPM -225.7% 46% evidence | 10.0/20 P/E — · PEG — 0% evidence | 15.7/20 RS sector 29.1% · RS bench 45.7% · 1Y —9 of 12 weeks ahead to 2021-06-30 70% evidence | |
| Exact sum: 17.1 + 6.9 + 10 + 15.7 = 49.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44Sai Parenterals LtdSAIPARENT | 37.4/100Thin evidence · provisional38% evidence | ASLEEP | 13.7/35 Revenue — · PAT — · OPM change -1 pp 32% evidence | 5.1/25 ROCE 5.3% · OPM 13.2% 95% evidence | 8.6/20 P/E 111× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —6 of 9 weeks ahead 0% evidence |
| Exact sum: 13.7 + 5.1 + 8.6 + 10 = 37.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Alembic Pharmaceuticals Ltd's share price today?
Alembic Pharmaceuticals Ltd trades at ₹811, −14.3% over the past year. The company is valued at ₹15,940 Cr. The stock sits at 55% of its 52-week range of ₹674–₹925, +0.0% versus its 200-day average. On the tape, the price is building a base, 6 weeks in. — as of 11 September 2026.
What were Alembic Pharmaceuticals Ltd's latest quarterly results?
Alembic Pharmaceuticals Ltd reported revenue of ₹2,150 Cr and net profit of ₹172 Cr for the Jun 26 quarter. Revenue rose 25.7% and profit rose 11.7% year on year. Earnings per share were ₹8.80. The operating margin was 15.0%, 1.0 pp lower than a year earlier. — as of 11 September 2026.
What is Alembic Pharmaceuticals Ltd's revenue?
Alembic Pharmaceuticals Ltd reported revenue of ₹2,150 Cr in the Jun 26 quarter, +25.7% year on year. For the full FY26 fiscal year, revenue was ₹7,345 Cr (+10.1%). Over the last 10 years revenue compounded at 8.8% a year. — as of 11 September 2026.
What is Alembic Pharmaceuticals Ltd's profit?
Alembic Pharmaceuticals Ltd earned ₹172 Cr of net profit in the Jun 26 quarter, +11.7% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹671 Cr. The operating margin ran 15.0% in the latest quarter. — as of 11 September 2026.
What is Alembic Pharmaceuticals Ltd's market cap?
Alembic Pharmaceuticals Ltd's market capitalisation is ₹15,940 Cr at a share price of ₹811. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Alembic Pharmaceuticals Ltd's P/E ratio?
Alembic Pharmaceuticals Ltd trades at a P/E of 21.4×, at the 44th percentile of its own 11-year range, against a long-run median of 23.6×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Alembic Pharmaceuticals Ltd pay a dividend?
Yes — Alembic Pharmaceuticals Ltd's dividend payout was 35% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is Alembic Pharmaceuticals Ltd overvalued?
On its own history, Alembic Pharmaceuticals Ltd looks mid-range: its P/E of 21.4× sits at the 44th percentile of its 11-year range (long-run median 23.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is Alembic Pharmaceuticals Ltd growing?
Yes — Alembic Pharmaceuticals Ltd is growing: latest-quarter revenue +25.7% year on year, profit +11.7%, and the margin −1.0 pp at 15.0%. The 10-year compound rates are 8.8% (revenue) and −0.7% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Alembic Pharmaceuticals Ltd performing?
Alembic Pharmaceuticals Ltd is building a base, 6 weeks in. Its latest quarter's revenue rose 25.7% and profit rose 11.7% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 14 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is Alembic Pharmaceuticals Ltd in?
Turning around — profit growth swung from −4.4% at the trough to +14.6% off a 4-quarter-old trough, ROCE holding at 13.7%. The read comes from the last 12 quarters of growth (revenue growth +14.1% latest, profit growth +14.6% latest, eps growth +15.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is Alembic Pharmaceuticals Ltd in an uptrend?
No — the price is building a base (week 6 of stage 1), trading +0.0% versus its 200-day average and at 55% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Alembic Pharmaceuticals Ltd beating the market?
On recent form, yes — Alembic Pharmaceuticals Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 14 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +32% against the NIFTY 500's +267% — behind the index over the full window. — as of 11 September 2026.
Will Alembic Pharmaceuticals Ltd's share price go up?
This page publishes no price forecast for Alembic Pharmaceuticals Ltd. What it measures instead: the share price is ₹811, the price is building a base 6 weeks in. Its P/E of 21.4× sits at the 44th percentile of its own 11-year range. — as of 11 September 2026.
Who owns Alembic Pharmaceuticals Ltd?
Promoters hold 69.9% of Alembic Pharmaceuticals Ltd, foreign institutions 4.2%, domestic institutions 15.9% and the public 10.0% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 11 September 2026.
Does Alembic Pharmaceuticals Ltd have too much debt?
No — Alembic Pharmaceuticals Ltd's debt-to-equity is 0.25, and operating profit covers the interest bill 12×. FY26 borrowings were ₹1,430 Cr against equity of ₹5,675 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Alembic Pharmaceuticals Ltd's capex?
Alembic Pharmaceuticals Ltd spent ₹1,636 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹722 Cr, with ₹683 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Alembic Pharmaceuticals Ltd's cash flow?
Alembic Pharmaceuticals Ltd generated ₹783 Cr of operating cash flow in FY26 and ₹61.0 Cr of free cash flow after ₹722 Cr of capital spending. Reported profit that year was ₹671 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Alembic Pharmaceuticals Ltd's profit real cash?
Yes — over the last 3 fiscal years, 90% of Alembic Pharmaceuticals Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹783 Cr against reported profit of ₹671 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Alembic Pharmaceuticals Ltd in its business cycle?
Alembic Pharmaceuticals Ltd's FY26 operating margin was 15.0%, against a 13-year band of 12.0%–32.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What growth does Alembic Pharmaceuticals Ltd's price assume?
At its price on 13 June 2026, Alembic Pharmaceuticals Ltd was priced for profit growth of about 13.7% a year. Profit itself has compounded −0.7% a year over the past 10 years. The figure reads the multiple backwards: the growth a buyer at that price was already paying for. — as of 11 September 2026.
What could break the Alembic Pharmaceuticals Ltd story?
The sharpest disagreement: annual EPS moved +15.7% against a −14.3% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Alembic Pharmaceuticals Ltd a stock worth studying right now?
This is not investment advice. The machine read: Alembic Pharmaceuticals Ltd's earnings have outrun its stock. EPS grew +15.7% in a year against a −14.3% price move. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!